Patents by Inventor Alexey Alexandrovich Lugovskoy

Alexey Alexandrovich Lugovskoy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160122438
    Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
    Type: Application
    Filed: February 27, 2013
    Publication date: May 5, 2016
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Jason BAUM, Bryan JOHNSON, Alexey Alexandrovich LUGOVSKOY, Lihui XU, Neeraj KOHLI, Jonathan Basil FITZGERALD, Sharlene ADAMS
  • Publication number: 20150231219
    Abstract: Provided are methods for the administration of therapeutic bispecific anti-IGF-1R and anti-ErbB3 antibodies, either alone or in combination with other anti-cancer therapeutics.
    Type: Application
    Filed: April 2, 2013
    Publication date: August 20, 2015
    Inventors: Alexey Alexandrovich Lugovskoy, Jason Baum, Sharlene Adams, Bryan Johnson, Jian Tang
  • Patent number: 8892364
    Abstract: The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: November 18, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Scott Glaser, Stephen Demarest, Brian Robert Miller, William B. Snyder, Xiufeng Wu, Norman Wang, Lisa J. Croner, Alexey Alexandrovich Lugovskoy
  • Patent number: 8618252
    Abstract: The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: December 31, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Graham K. Farrington, Alexey Alexandrovich Lugovskoy, Werner Meier, John K. Eldredge, Ellen Garber
  • Publication number: 20130236459
    Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
    Type: Application
    Filed: February 27, 2013
    Publication date: September 12, 2013
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Jason BAUM, Bryan JOHNSON, Alexey Alexandrovich LUGOVSKOY, Lihui XU, Neeraj KOHLI, Jonathan Basil FITZGERALD, Sharlene ADAMS
  • Patent number: 8476409
    Abstract: Provided are bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: July 2, 2013
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Jason Baum, Bryan Johnson, Alexey Alexandrovich Lugovskoy, Lihui Xu, Neeraj Kohli, Jonathan Basil Fitzgerald, Sharlene Adams
  • Patent number: 8349324
    Abstract: The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: January 8, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Alexey Alexandrovich Lugovskoy, Karl Hanf, You Li, Kenneth Simon, Herman Van Vlijmen
  • Publication number: 20120269812
    Abstract: Provided herein are novel monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. Novel antiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
    Type: Application
    Filed: April 19, 2012
    Publication date: October 25, 2012
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Jason BAUM, Bryan JOHNSON, Alexey Alexandrovich LUGOVSKOY, Lihui XU, Neeraj KOHLI, Jonathan Basil FITZGERALD, Sharlene ADAMS
  • Publication number: 20120244163
    Abstract: Disclosed are bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-IGF-1R antibody and an anti-ErbB3 antibody connected by a linker are described herein. These bispecific agents are capable of antagonizing signal transduction by both of the IGF-1 and the ErbB signaling pathways and are useful in inhibiting the proliferation of tumor cells whose growth involves the signaling activity of both pathways.
    Type: Application
    Filed: April 10, 2012
    Publication date: September 27, 2012
    Applicants: DYAX CORP., MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Birgit SCHOEBERL, Ulrik NIELSEN, Arthur J. KUDLA, Arumugam MURUGANANDAM, David BUCKLER, Alexey Alexandrovich LUGOVSKOY, Jonathan Basil FITZGERALD, Lihui XU, Neeraj KOHLI
  • Publication number: 20120003210
    Abstract: The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.
    Type: Application
    Filed: December 13, 2010
    Publication date: January 5, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Graham K. FARRINGTON, Alexey Alexandrovich LUGOVSKOY, Werner MEIER, John K. ELDREDGE, Ellen GARBER
  • Publication number: 20110243966
    Abstract: The present invention features inter alia polypeptides comprising an Fc region comprising genetically-fused Fc moieties. In addition, the instant invention provides, e.g., methods for treating or preventing a disease or disorder in subject by administering the binding polypeptides of the invention to said subject.
    Type: Application
    Filed: March 14, 2011
    Publication date: October 6, 2011
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Graham K. FARRINGTON, Amna SAEED-KOTHE, Ellen GARBER, Alexey Alexandrovich LUGOVSKOY
  • Patent number: 8021661
    Abstract: The invention pertains to humanized forms of an anti-CRIPTO antibody and portions thereof. In one embodiment, the variable regions of these antibodies or polypeptides comprising them (e.g., full-length antibodies or domain deleted antibodies) can be used to treat disorders, such as cancer.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: September 20, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Scott Glaser, Herman Van Vlijmen, Alexey Alexandrovich Lugovskoy, Michele Sanicola-Nadel, Xiufeng Wu, Ellen Garber, Jose William Saldanha
  • Patent number: 7960142
    Abstract: The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: June 14, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Scott Glaser, Stephen Demarest, Brian Robert Miller, William B. Snyder, Xiufeng Wu, Norman Wang, Lisa J. Croner, Alexey Alexandrovich Lugovskoy
  • Patent number: 7951918
    Abstract: The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules.
    Type: Grant
    Filed: March 19, 2007
    Date of Patent: May 31, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Scott Glaser, Stephen Demarest, Brian Robert Miller, William B. Snyder, Xiufeng Wu, Norman Wang, Lisa J. Croner, Alexey Alexandrovich Lugovskoy
  • Publication number: 20100093980
    Abstract: The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies.
    Type: Application
    Filed: December 1, 2009
    Publication date: April 15, 2010
    Applicant: Biogen Idec MA Inc.
    Inventors: Alexey Alexandrovich Lugovskoy, Karl Hanf, You Li, Kenneth Simon, Herman van Vlijmen
  • Patent number: 7678371
    Abstract: The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies.
    Type: Grant
    Filed: March 6, 2006
    Date of Patent: March 16, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Alexey Alexandrovich Lugovskoy, Karl Hanf, You Li, Kenneth Simon, Herman Van Vlijmen
  • Publication number: 20100008906
    Abstract: The invention pertains to humanized forms of an anti-CRIPTO antibody and portions thereof. In one embodiment, the variable regions of these antibodies or polypeptides comprising them (e.g., full-length antibodies or domain deleted antibodies) can be used to treat disorders, such as cancer.
    Type: Application
    Filed: July 3, 2007
    Publication date: January 14, 2010
    Inventors: Scott Glaser, Herman Van Vlijmen, Alexey Alexandrovich Lugovskoy, Michele Sanicola-Nadel
  • Publication number: 20090258420
    Abstract: The present invention features inter alia altered binding polypeptides having engineered cysteine residues or analogs thereof at a predetermined site within, for example, a constant region domain or a portion thereof. The engineered cysteine residues or analogs thereof provide sites for conjugating effector moieties (e.g. diagnostic or therapeutic agents) that impart novel functionality to the binding polypeptide, preferably without interfering with a desirable property (e.g. an Fc-mediated effector function). The invention includes methods for the rational design of such altered polypeptides, as well as methods for modifying (ie. conjugating) the altered polypeptides with desirable effector moieties. Particular modified binding polypeptides (ie. immunoconjugates) of altered binding polypeptides and methods for utilizing such modified binding polypeptides as protein-based therapeutics are also provided.
    Type: Application
    Filed: January 30, 2008
    Publication date: October 15, 2009
    Inventors: Herman van Vlijmen, Alexey Alexandrovich Lugovskoy, Kathryn Strauch, Frederick R. Taylor
  • Publication number: 20090252729
    Abstract: The present invention features inter alia polypeptides comprising an Fc region comprising genetically-fused Fc moieties. In addition, the instant invention provides, e.g., methods for treating or preventing a disease or disorder in subject by administering the binding polypeptides of the invention to said subject.
    Type: Application
    Filed: May 14, 2008
    Publication date: October 8, 2009
    Inventors: Graham K. Farrington, Amna Saeed-Kothe, Ellen Garber, Alexey Alexandrovich Lugovskoy
  • Publication number: 20090155255
    Abstract: The invention is based, at least in part, on the development of multivalent and stabilized forms of CD23 binding molecules and methods of use thereof for the treatment of immune cell disorders, including leukemias or lymphomas such as CLL.
    Type: Application
    Filed: September 29, 2008
    Publication date: June 18, 2009
    Applicant: Biogen Idec MA Inc.
    Inventors: Scott Glaser, Brian Robert Miller, Alexey Alexandrovich Lugovskoy, Stephen Demarest, Ann Maclaren, William B. Snyder